833-NSSUPRT (833-677-8778)
Monday–Friday, 8 AM-8 PM ET
Our experienced, knowledgeable team at NS Support is dedicated to assisting patients, their caregivers, and healthcare professionals throughout the treatment journey. We’re committed to being there for you every step of the way.
Here’s what to do:
1.
Download and save the editable Patient Start Form
2.
Submit a completed and signed form to NS Support
Your completed Patient Start Form with a valid prescriber signature will allow NS Support to start a benefits investigation for your patient. A signed Patient Authorization Form is needed to complete NS Support enrollment, receive program offerings, and enroll in cost support programs if eligible.
More support for physicians and their practices:
Support for patients and their caregivers:
Monday–Friday, 8 AM–8 PM ET
*Program covers the cost of the medication only and does not cover the cost to administer the infusion.Affordability Options Brochure.
See full Eligibility Requirements & Terms and Conditions in theSummarizes the clinical evidence of the efficacy and safety of VILTEPSO and other product features
Provides information on how to prescribe, dose, and administer VILTEPSO as infusion therapy
Watch a video overview about how to administer a VILTEPSO infusion
Provides information on initiating therapy and helping patients afford their treatment
Provides coding and billing information and sample claim forms for home infusion, physician offices, and hospital outpatient departments (HOPD) to process claims for VILTEPSO
Explains the features of VILTEPSO in treating DMD, including efficacy and safety
Answers common questions about what VILTEPSO does, how it works, and other concerns you may have
Introduces patients and caregivers to their NS Pharma and NS Support teams and explains their journey to treatment
Helps you better understand the weekly infusion process and address questions in advance of the first session
Helps commercially insured patients with their medication costs
Provides information about government-funded health insurance and financial assistance
Includes a list of foundations and advocacy groups that may be able to provide assistance to patients with DMD
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For more information about VILTEPSO, see full Prescribing Information.
For more information about VILTEPSO, see full Prescribing Information.